Scotiabank analyst Sung Ji Nam raised the firm’s price target on Guardant Health (GH) to $60 from $57 and keeps an Outperform rating on the shares. The company’s Q2 results beat expectations across the board and FY25 revenue guidance was raised once again, the analyst tells investors. The company’s Guardant360 portfolio shows continued strength and Shield has exceeded the firm’s expectations in its first year commercially, Scotiabank adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $63 from $60 at TD Cowen
- 3 Best Stocks to Buy Now, 7/31/2025, According to Top Analysts
- Guardant Health’s Strong Performance and Growth Potential Justify Buy Rating Despite V2 Data Delay Concerns
- Guardant Health Reports Strong Q2 2025 Growth
- Guardant Health’s Strong Performance and Strategic Focus Drive Buy Rating